Safety and Tolerability of Intravenous and Subcutaneous AZD1163 in Rheumatoid Arthritis: A Placebo-Controlled Study in Healthy Volunteers

The primary objective of this study is to evaluate the **safety** and **tolerability** of intravenous (IV) and subcutaneous (SC) administration of AZD1163 in healthy volunteers. This is clinically relevant as it aims to determine the potential adverse effects and overall acceptability of the drug delivery methods, which is crucial for ensuring patient safety in future therapeutic applications, particularly for conditions such as **Rheumatoid Arthritis**. No secondary objectives are specified for this study.

The clinical trial involves a total of **70 participants** diagnosed with **Rheumatoid Arthritis**. The study population includes both male and female subjects, with an age range categorized under code "3", which typically represents adults. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The general health status of the participants is not specified, nor are any particular lifestyle considerations such as diet or physical activity. The sponsor has not provided detailed information regarding the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed as a **placebo-controlled** study to evaluate the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of AZD1163 in healthy volunteers. The trial is structured as a **randomized**, double-blind, controlled study, ensuring that neither the participants nor the researchers know who is receiving the active treatment or the placebo, thus minimizing bias. The trial is set to commence recruitment on April 18, 2024, and is expected to conclude by February 21, 2026, indicating an overall duration of approximately 22 months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation to ensure that participants meet the necessary health standards for inclusion in the study. Following successful screening, participants will be randomized to receive either the investigational product or a placebo. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health, assess the safety and tolerability of the treatment, and collect data on any adverse events. These visits are crucial for ensuring participant safety and the integrity of the trial data.

The end-of-study visit will mark the conclusion of the participant's involvement in the trial. During this visit, final assessments will be conducted to gather comprehensive data on the long-term effects of the treatment. The expected length of participant involvement will vary depending on the specific protocol but will generally align with the overall trial duration. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with the study protocol, or withdraw consent. Such conditions are in place to prioritize participant safety and maintain the scientific validity of the trial.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific information, additional relevant details about drug administration, dosing schedules, and participant compliance monitoring are also not included. The absence of data on the **experimental medication** and non-experimental treatments limits the ability to provide a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on April 18, 2024, with an estimated completion date of February 21, 2026. Although specific efficacy endpoints are not detailed, Phase 1 trials often utilize various parameters such as **biomarker** levels or symptom improvement scores to evaluate efficacy. These parameters are usually measured at predefined intervals throughout the trial duration. The data collected will be analyzed to determine the potential therapeutic effects of the investigational product. The trial will adhere to rigorous scientific and ethical standards to ensure the reliability and validity of the efficacy assessments.